Endostar continuous intravenous infusion combined with S-1 and oxaliplatin chemotherapy could be effective in treating liver metastasis from gastric cancer | Zendy

Honglan Yang | Zendy; Yanmin Sui | Zendy; Xing-Jun Guo | Zendy; Xiaojing Tan | Zendy; Yan Li | Zendy; Minglin Wang | Zendy

Open Access

Endostar continuous intravenous infusion combined with S-1 and oxaliplatin chemotherapy could be effective in treating liver metastasis from gastric cancer

Author(s) -

Honglan Yang,

Yanmin Sui,

Xing-Jun Guo,

Xiaojing Tan,

Yan Li,

Minglin Wang

Publication year - 2017

Publication title -

journal of cancer research and therapeutics

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.475

H-Index - 39

eISSN - 0973-1482

pISSN - 1998-4138

DOI - 10.4103/0973-1482.204880

Subject(s) - oxaliplatin , medicine , regimen , bone marrow suppression , chemotherapy , gastroenterology , metastasis , adverse effect , cancer , oncology , colorectal cancer

Endostar is a new vascular epithelial inhibitor, which is reported to be effective in treating liver metastasis from gastric cancer. However, the optimal therapeutic regimen of Endostar remains unclear. Thus, our study aimed to examine the efficacy and safety of Endostar continuous intravenous infusion combined with S-1 and oxaliplatin (SOX) chemotherapy in treating such patients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research